April 2016 in “Journal of The American Academy of Dermatology” Dutasteride is more effective than finasteride for hair growth with similar side effects.
August 2025 in “Journal of the American Academy of Dermatology”
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
The research created new azasteroids and pseudoazulenyl nitrones, which could be useful in medicine.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
30 citations
,
July 2001 in “BJUI” Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
11 citations
,
April 2018 in “Epilepsy research” Letrozole reduces seizures but not brain damage in mice.
7 citations
,
January 2019 in “Brazilian Journal of Pharmaceutical Sciences” Maidenhair fern extract reduced anxiety and depression in rats and may work due to its antioxidant and anti-inflammatory properties.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
February 2023 in “European Journal of Dermatology” The document concludes that injecting dutasteride into the skin (mesotherapy) can effectively treat common hair loss in both men and women.
January 2022 in “eJournal Kedokteran Indonesia” Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
8 citations
,
October 2024 in “Cochrane Database of Systematic Reviews” Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
7 citations
,
January 2018 in “Reproduction” Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.
September 2015 in “Korean Journal of Clinical Pharmacy” Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
September 2025 in “Dermatology and Therapy” The treatment improved hair growth and was well-received without side effects.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
May 2018 in “Dermatologic Surgery”
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.